Previously, we demonstrated that Prx II is important for survival of the gefitinib-resistant A549 (A549/GR) cell line, an NSCLC cell line derived by repeated exposure to gefitinib. Therefore, in this study, we used A549/GR cells to investigate the role of Prx II in GR NSCLC stemness. Initially, to explore the stemness characteristics and investigate the association of Prx II with those stemness characteristics, we successfully isolated a stem cell-like population from A549/GR cells. A549/GR CD133+ cells possessed important cancer stemness characteristics, including the abilities to undergo metastasis, angiogenesis, self-renewal, and to express stemness genes and epithelial–mesenchymal transition (EMT) markers. However, those characteristics were abolished by knocking down Prx II expression. MicroRNA 122 (miR-122) targets Prx II in A549/GR cancer stem cells (CSCs), thereby inhibiting the stemness characteristics in vitro and in vivo. Next, we investigate whether miR-122 overexpression was associated with Prx II expression and Prx-II-induced stemness characteristics, we transfected miR-122 into A549/GR CSCs. MiR-122 inhibited A549/GR stemness by downregulating the Hedgehog, Notch, and Wnt/β-catenin pathways. Taken together, our data suggest that Prx II promotes A549/GR stemness, and that targeting Prx II and miR-122 is a potentially viable strategy for anti-cancer-stem cell therapy in GR NSCLCs.
Peroxiredoxins (Prxs) comprise an important superfamily of cysteine (Cys)-based antioxidant enzymes, which are divided into three subclasses based on the number of conserved Cys residues participating in the redox reaction, i.e., the typical 2-Cys Prxs (Prxs I–IV), an atypical 2-Cys Prx (Prx V), and an atypical 1-Cys Prx (Prx VI) [1, 2]. These members of the Prx family have been frequently reported to be upregulated in many cancers, including breast, cervical, prostate, colorectal, mesothelioma, brain, and lung cancer [3,4,5,6,7,8]. Among the Prxs, Prx I, II, IV, and VI are aberrantly expressed with various potential effects on tumor progression in lung carcinomas, which is the leading cause of cancer-related death worldwide . Previously, we showed the role of Prx II in a gefitinib-resistant (GR) A549 (A549/GR) non-small cell lung cancer (NSCLC) cell line, which was derived from the parental A549 cell line by repeated exposure to gefitinib . NSCLC is one of the two main histological subtypes of lung cancers and represents most cases of lung cancer . Aberrant expression of Prx II in NSCLCs has also been associated with induced tumor cell growth and proliferation via pJNK activation . Furthermore, accumulating evidence has suggested that Prx II maintains cancer stem-like properties and induces the growth of colorectal cancer by activating the Hedgehog (HH) and Wnt/β-Catenin signaling pathways [11,12,13]. Prx II also maintains the stemness of hepatocellular carcinoma (HCC) stem cells via redox regulation . Cancer stem cells (CSCs) are considered to be responsible for cancer progression, metastasis, and resistance to therapy . Thus, in this study, we mainly focused on Prx II expression and Prx II-mediated stemness characteristics in A549/GR stem cells.
MicroRNAs (miRNAs) are small non-coding RNAs with the ability to regulate the expression of oncogenes, tumor suppressors, and numerous other genes and thereby influence the development of cancers . Many recent studies have been aimed at developing identification systems for cancer-related miRNAs and their target genes, in order to elucidate the role of miRNAs in cancers . Among them, miR-122 has been implicated as a tumor-suppressor gene in various types of cancers . Recent studies have showed that miR-122 targets oncogenes, such as cyclin G1 and Bcl-2, thereby suppressing tumor proliferation [18, 19]. Overexpression of miR-122 in NSCLC cells induces chemo-sensitization for gemcitabine and radio-sensitization. Moreover, apoptosis and cell cycle arrest can be induced by miR-122 overexpression in NSCLC cells [19, 20]. Therefore, previous studies showed the potential application of miR-122 in NSCLC treatment. More importantly, one study demonstrated that miR-122 targets Prx II in HCC. MiR-122 downregulates Prx II expression by binding to Prx II and inhibits HCC cell growth by inducing apoptosis . Here, we investigated the Prx II expression and mechanistic links that could explain the potential of Prx II in driving CSC properties, such as stemness, cell proliferation, metastasis, and angiogenesis in A549/GR stem cells. We also showed the direct effect of miR-122 in inhibiting Prx II expression. Thus, our findings provide new insights into the miR-122-mediated downregulation of A549/GR stem cell properties via Prx II inhibition.
Materials and methods
Cell culture, transfections, and generating stable cell lines
A549, A549/GR, A549/GR CD133–, A549 pCMV-Prx II, H460, H460/GR, HCC827, HCC827/GR cells, HCC827/GR shCON, and HCC827/GR shPrx II cells were grown in RPMI 1640 (Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS: Hyclone, Logan, UT, USA), penicillin (100 U/ml) and streptomycin (100 mg/ml). A549/GR CD133+, A549/GR CD133+ shPrx II, and A549/GR CD133+ shCON cells were cultured in the above-mentioned complete medium supplemented with 10 ng/ml human epidermal growth factor (Sigma-Aldrich, St. Louis, LO, USA) and 20 ng/ml basic fibroblast growth factor (Koma Biotech, Daejeon, Korea). Transfection of the pCMV-Prx II vector and establishing the shPrx II and shCON cell lines were performed as described previously [7, 22]. MiR-122 was expressed from a DNA plasmid that was transfected using the Lipofectamine 2000 reagent (Invitrogen) according to manufacturer’s instructions. To screen for stable cell lines, the cells were plated in selective medium containing G418 (1000–2000 μg/ml, Invitrogen) for ~3 weeks, beginning at 48 h post transfection. The selective medium was replaced every 3 days. GFP-positive cells were selected.
Magnetic-activated cell sorting to separate the CD133+ CSC population
A549/GR cells were separated on a magnetic-activated cell sorting column after labeling them with a primary anti-CD133 antibody (Miltenyi Biotech, Germany) according to the manufacturer’s instructions. The purity of the sorted CSCs was evaluated by western blotting.
Cell proliferation and apoptosis assays
Cells were seeded at a density of 5 × 103 cells/well in a 96-well plate, and the role of Prx II and miR-122 in A549/GR CSC proliferation was studied using the EZ-Cytox Kit (DoGenBio, Korea. Catalog number: EZ-3000), according to the manufacturer’s instructions. The absorbance in each well was measured at 450 nm. To detect apoptosis, cells were prepared using the Propidium Iodide (PI), Annexin V Detection Kit (BD Biosciences), per the manufacturer’s instructions, and analyzed by flow cytometry (FACSCalibur, BD Biosciences).
Western blot analysis
Collected A549 and A549/GR cells were lysed in RIPA buffer (150 mM NaCl, 1% Nonidet p-40, 50 mM Tris, pH 8.0, and a protease inhibitor cocktail). Thirty micrograms of each sample was separated by SDS-PAGE and transferred to a nitrocellulose membrane (Bio-Rad, USA). Western blotting was performed with rabbit or mouse antibodies against Prx II: LF-PA0091 (AbFrontier, Seoul, South Korea), CD133: PA2049 (Boster Bio, CA, USA), Nanog: sc-293121, OCT3/4: sc-9081, Sox2: sc-365823 (Santa Cruz Biotechnology), VEGFR2: sc-6251, E-cad: sc-7870, Vimentin: sc-6260 (Santa Cruz Biotechnology), Shh: 2207 s, Gli-1: 3538 s, Notch 1: 3268 s (Cell Signaling Technology), CXCR4: YF-MA16239, STAT3: LF-MA30485,pSTAT3 (Tyr 705): LF-PA20474, pSTAT3 (Tyr-727): LF-PA20473 Hes-1: YF-MA11051, and β-Catenin: YF-MA10213 (AbFrontier). Protein expression levels were detected using Super signal West Pico PLUS Chemiluminescent Substrate (Thermo Fisher, #34577).
ROS levels in A549/GR shCON and shPrx II cells and A549/GR cells transfected with miR-122 and miR-NC were determined using DCF-DA (Invitrogen). Cells were incubated with 20 mM DCF-DA for 15 min at 37 °C and then washed with 1X PBS. Fluorescence due to DCF-DA deacetylation and oxidation was analyzed on a FACSCalibur flow cytometer (BD Biosciences).
Migration and invasion assays were performed using transwell 24-well chambers with 8.0-µM pore polycarbonate membranes (Merck Millipore, Darmstadt, Germany) without (migration) or with (invasion) Matrigel. Briefly, 200-µl volumes of A549/GR cell suspensions in medium containing 0.5% FBS were added separately to the upper chambers (1 × 105 cells/chamber). In each case, the bottom chamber was filled with 800 µI of medium supplemented with 20% FBS as a chemoattractant. The cells were then incubated for 24 h at 37 °C in 5% CO2. Cells that passed through the coated membrane to the lower surface were then fixed with 4% paraformaldehyde and stained with 0.1% crystal violet for 1 h. Images were captured using a microscope.
A549/GR CD133+ and CD133− cells were plated in a six-well plate at 1 × 106 cells/well and allowed to grow into a monolayer. At 90% confluence, the complete medium was replaced with serum-free medium and the cells were cultured overnight until a complete monolayer formed. Using a wound maker (Essen Bioscience, Ann Arbor, MI 48108, USA), a linear scratch was made in the cell monolayer. Cells were rinsed with 1X PBS and fresh complete media was added. Photomicrographs were taken of the migrated cells at 0 and 24 h using the IncuCyte Live-Cell Analysis System (IncuCyte).
Sphere-formation and ICC assays
A549/GR shCON, shPrx II, CD133+, and CD133− cells (2 × 103 cells/well) were seeded in a six-well Ultra Low Cluster plate (Corning Inc., Corning, NY, USA) and cultured for 10 days in suspension in serum-free Dulbecco’s modified Eagle’s medium/F12 (Gibco, Grand Island, NY, USA) containing B27 supplement (1: 50; Invitrogen), 20 ng/ml EGF (Calbiochem, CA, USA), and 0.5% bovine serum albumin (Sigma-Aldrich). The spheres were imaged with an inverted microscope and counted. Sphere-formation efficiency was calculated as the number of colonies/input cells × 100%. ICC staining of spheres was performed following the steps of the ICC assay, as described below.
A549 cells and A549/GR cells were fixed with 3.7% formaldehyde in 1X PBS for 10 min at room temperature. They were then blocked with 1X PBS containing 0.5% Triton X-100 and 1% bovine serum for 60 min at room temperature and incubated with primary antibodies for 18 h. On the following day, the cells were washed with 1X PBS with Tween 20 and incubated with secondary antibodies for 2 h at room temperature. Nuclei were visualized by 4’,6-diamidino-2-phenylindole (DAPI) staining. Nuclear staining was observed qualitatively under a microscope after 20 min of DAPI staining, and images were acquired.
A549/GR CD133–, A549/GR CD133+ shCON, shPrx II, miR-122, and miR-NC-transfected cells (1 × 103 cells/well) were plated in six-well plates and maintained in an incubator at 37 °C with 5% CO2 for 7 days. Cells were then washed with 1X PBS, fixed with 3.7% formaldehyde for 10 min, treated with methanol for 20 min, and stained with crystal violet for 30 min. The plates were washed three times with 1X PBS prior to image capturing.
Xenograft model and optical imaging
Mice were maintained and used for experiments, according to a protocol approved by the Institutional Animal Care and Use Committee of Jeju National University (Jeju, South Korea). The tumorigenicity of A549/GR CD133+ cells transfected with miR-122 or miR-NC was assayed after subcutaneously inoculating 1 × 105 cells in a mixture of 100 µl Matrigel (Sigma-Aldrich) and 1X PBS into the flanks of 8-week-old athymic BALB/c female nude mice (n = 5/group). Tumor growth was observed at 35 days post inoculation by IRDye® 800CW 2-DG (radiolabeled 2-deoxy-D-glucose [2-DG])-based optical imaging of xenograft models.
Paraffin-embedded tumor tissues were cut in 4-μm sections, deparaffinized in xylene, and rehydrated through a graded ethanol series. Next, the sections were rinsed three times in 1X PBST (PBS with Tween 20). The sections were then blocked in 1X PBS containing 0.5% Triton X-100 and 5% sheep serum for 30 min at room temperature before incubating them overnight at 4 °C with a rabbit anti-Prx II polyclonal antibody (AbFrontier technology, Seoul, South Korea) and a mouse anti-vimentin monoclonal antibody (Santa Cruz Biotechnology). Sections were again rinsed three times in 1X PBST. To detect the bound primary antibodies, the sections were incubated in the dark at room temperature for 90 min with goat anti-rabbit and goat anti-mouse antibodies (Santa Cruz Biotechnology). Slides were counterstained for 20 min in the dark with DAPI diluted in 1X PBS before visualization and image capturing under a microscope.
All experiments were repeated five times, and data are presented as the mean ± standard error. Statistical analyses were performed using the Statistical Package for the Social Sciences (SPSS version 20.0.1; SPSS, Chicago, IL, USA). Statistically significant difference among treatment groups were determined via one-way ANOVA and Fisher’s least significant difference (LSD) test. P-values <0.05 are considered significant.
Prx II expression mediated the enhanced stemness of GR NSCLC cells
Prx II is highly expressed in A549/GR cells, but not in parental A549/MOCK cells . Western blot analysis was performed to verify that Prx II was expressed in A549/GR cells and to observe Prx II expression in other GR NSCLC cells. As expected, Prx II was expressed in A549/GR cells, but not in A549/MOCK cells. Other NSCLC cell lines (MOCK) and their GR variants showed relatively similar Prx II-expression levels. Parallel experiments showed that higher expression of the CSC marker, CD133 was present in GR NSCLC cells, compared with MOCK cells (Fig. 1a). High expression of Prx II and CD133 in A549/GR cells was confirmed by performing immunocytochemistry (ICC) assays (Fig. 1b).
To examine the relationship between Prx II expression and the enhanced stemness of GR NSCLC cells in greater detail, we generated cell lines expressing short hairpin RNAs (shRNAs) against Prx II or a control target. GR-shPrx II (Prx II knockdown) and GR-shCON (control) variants were established with the A549, H460, and HCC827 cell lines, as described in our previous report . Western blot assays validated the successful knockdown of Prx II in GR-shPrx II cells and showed that stemness was inhibited in GR NSCLC cells by Prx II knockdown, as observed by the reduced expression of CD133 and the stemness-related genes Nanog, Oct3/4, and Sox2 in GR-shPrx II, compared with GR-shCON cells (Fig. 1c).
Because, we observed significantly different Prx II expression in A549/MOCK and A549/GR cells compared with other NSCLC cell lines, we selected A549/GR cells for further experiments. We studied the effect of Prx II knockdown on reactive oxygen species (ROS) levels by performing dichloro-dihydro-fluorescein diacetate (DCF-DA) assays and measuring apoptosis by Annexin V staining. Increased percentages of DCF-DA- and Annexin V-positive A549/GR-shPrx II cells showed the induction of ROS levels and apoptosis by Prx II knockdown (Fig. 1d, e). Prx II knockdown suppressed the self-renewal capacity of A549/GR cells, as observed by diminished sphere-formation capacity in A549/GR-shPrx II, compared with A549/GR-shCON cells (Fig. 1f). These observations imply that Prx II mediates the stemness of A549/GR cells.
Cancer stem-like properties were exhibited in A549/GR CD133+ cells with high Prx II expression
The cell surface marker, CD133 has been used to isolate CSC (CD133+ cell) populations . Our above results showed that some A549/GR cells expressed CD133. We separated the CD133+ subpopulation of A549/GR cells (A549/GR CD133+) from the A549/GR CD133– cells. Both subpopulations were examined for their cancer stem-like properties. High Prx II expression was observed in A549/GR CD133+ cells compared with A549/GR CD133– cells by western blotting (Fig. 2a) and ICC assays (Fig. 2a, b). Furthermore, western blotting showed the enhanced expression of CD133 and stemness-related genes Nanog, Oct3/4, and Sox2 in CD133+ cells compared with CD133– cells, in parallel with high Prx II expression (Fig. 2a). These data showed that the enhanced stemness of CD133+ cells correlated with high Prx II expression.
CSCs are characterized by high potentials for self-renewal, differentiation, and metastasis . Therefore, we further examined A549/GR CD133+ cells for those stem-like properties. We performed 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays and Annexin V staining to assess the proliferation of CD133+ cells. Increased viability and reduced numbers of Annexin V-positive CD133+ cells (versus CD133– cells) indicated that proliferation was enhanced due to inhibited apoptosis (Fig. 2c, d). CD133+ cells showed greater colony-formation ability in vitro than CD133– cells, confirming the enhanced cell proliferation of CD133+ cells (Fig. 2e). Increased self-renewal and differentiation abilities were observed through the larger size and increased number of CD133+ spheres in sphere-formation assays (Fig. 2f).
Next, wound-healing assays revealed that CD133+ cells were capable of significantly faster wound closure than CD133– cells (Fig. 2g), and a transwell assay with Matrigel demonstrated that CD133+ cells were more invasive than CD133– cells (Fig. 2h), indicating the higher metastatic capacity of CD133+ cells (as cell-migration ability is required for cancer metastasis) . Taken together, these results confirmed A549/GR CD133+ cells had stem cell characteristics and high-level Prx II expression.
Prx II knockdown diminished cell proliferation, metastasis, and angiogenesis in A549/GR CSCs
We then investigated whether Prx II is involved with the stem-like properties of A549/GR CSCs. Thus, we established Prx II-knockdown A549/GR CD133+ (shPrx II) and control A549/GR CD133+ (shCON) cell lines, as described in our previous study , and studied the effects of Prx II knockdown on A549/GR CSCs. Successful knockdown of Prx II was initially validated by western blot analysis and ICC assays. CD133 expression also was reduced in shPrx II cells compared with shCON cells, indicating the reduction of the CD133+ CSC population by Prx II knockdown (Fig. 3a, b). ROS levels and the proportion of Annexin V-positive cells increased in shPrx II cells compared with shCON cells, indicating that apoptosis was induced by Prx II knockdown (Fig. 3c, d). Reduced shPrx II cell proliferation (compared with that of shCON cells) was observed in MTT and colony-formation assays (Fig. 3e, f). These data indicated that Prx II knockdown negatively associated with A549/GR CSC proliferation.
To gain insight into how Prx II knockdown alters cancer cell metastasis, we performed transwell assays (Fig. 3g). Both the migration and invasion capacities were reduced by Prx II knockdown, compared with those of shCON cells. Furthermore, higher expression of the epithelial marker E-cadherin and lower expression of the mesenchymal marker Vimentin in shPrx II cells (relative to that in shCON cells) indicated the suppressing Prx expression inhibited the epithelial–mesenchymal transition (EMT) (Fig. 3h). Collectively, these results demonstrated that in vitro Prx II knockdown abolished the enhanced metastatic capacity of A549/GR CSCs.
To study the effects of Prx II knockdown on A549/GR CSC angiogenesis, we predicted the Prx II-interaction network with respect to stemness-related and angiogenesis-related genes using STRING software (Fig. 3i). Based on the STRING results, we checked the levels of C-X-C chemokine receptor type 4 (CXCR4), vascular endothelial growth factor receptor 2 (VEGFR2), phosphorylated VEGFR2 (pVEGFR2), signal transducer and activator of transcription 3 (STAT3), and phosphorylated STAT3 (pSTAT3) in shPrx II, compared with shCON cells. Our results showed the reduction of CXCR4 expression in shPrx II cells. In addition, the phosphorylation of VEGFR2 (Tyr 951, Tyr 1175) and STAT3 (Tyr 705) were inhibited in shPrx II cells, compared with that in shCON cells. However, phosphorylation at the Ser 727 site was not inhibited by Prx knockdown (Fig. 3j). ICC assays further confirmed the reduction of Prx II, VEGFR2 (Tyr 1175), CXCR4, and STAT3 (Tyr 705) production in shPrx II cells, compared with shCON cells(Fig. 3k, l). Moreover, the sphere ICC assay revealed a reduced sphere-formation ability and Prx II expression after Prx II knockdown (Fig. 3m). Together, these data indicated that Prx II negatively regulated A549/GR CSC proliferation, metastasis, and angiogenesis.
miR-122 mimic transfection suppressed cellular proliferation, metastasis, and angiogenesis of A549/GR CSCs by inhibiting Prx II
Prx II is a direct target of miR-122 in HCC . Therefore, we studied whether miR-122 targets Prx II in A549/GR CSCs. We thus measured the baseline expression of endogenous miR-122 in A549/GR CD133+ and CD133– cells. Real-time PCR showed that miR-122 expression was lower in CD133+ cells than in CD133− cells (Fig. 4a). We then prepared separate A549/GR CD133+ cell lines stably expressing miR-122 or miR-NC. MiR-122 expression was quantified by real-time PCR 3 days after transfection. Increased miR-122 expression validated the successful transfection (Fig. 4b). The miR-122 transfection was also evaluated by quantifying the percent of green fluorescent protein (GFP)-positive cells (Fig. 4c). Then, we checked whether miR-122 overexpression inhibited Prx II expression in A549/GR CSCs. As expected, the transfection of miR-122 substantially downregulated the Prx II expression in A549/GR CSCs, as evidenced by western blot analysis and ICC assays (Fig. 4d, e).
Next, we compared miR-122- and miR-NC-transfected A549/GR CSCs to gain further insight into how miR-122 affects CSC properties by inhibiting Prx II. MiR-122 increased the percentages of DCF-DA and Annexin V-positive cells (Fig. 4f, g) and reduced the time-dependent viability of A549/GR CSCs (Fig. 4h), revealing that miR-122-induced cell death by inhibiting Prx II in A549/GR CSCs. A colony-formation assay showed that miR-122 reduced the colony-forming ability and, thus, the proliferation of A549/GR CSCs (Fig. 4i). Transwell assays with or without Matrigel showed that miR-122 abolished the high invasiveness and migration abilities of A549/GR CSCs (Fig. 4j). Furthermore, smaller spheres and fewer spheres observed in sphere-formation assays indicated the reduction of the self-renewal ability of A549/GR CSC after miR-122 transfection (Fig. 4k). Similar to the effects of Prx II knockdown, western blot analysis showed that miR-122 transfection downregulated CXCR4 expression, as well as VEGFR2 (Tyr 1175) and STAT3 (Tyr 705) phosphorylation, indicating that angiogenesis was inhibited (Fig. 4l). Western blotting also indicated that increased E-cadherin expression and decreased vimentin expression after miR-122 transfection inhibited the EMT in A549/GR CSCs (Fig. 4m). Taken together, these findings suggested that miR-122 suppressed the CSC properties of A549/GR cells by inhibiting Prx II.
Transfection of miR-122 led to more profound inhibitory effects of tumor growth in vivo via Prx II inhibition
In vivo studies were conducted to evaluate the effects of miR-122 on A549/GR CSCs in more depth. As shown in Fig. 5a, miR-122 significantly decreased tumor growth, as observed by the smaller tumor sizes of miR-122-transfected tumors compared to the miR-NC-transfected tumors. Immunofluorescence assays showed that Prx II and vimentin expression levels were reduced in vivo in miR-122-transfected tumor tissues compared with miR-NC-transfected tumor tissues, indicating that miR-122 targets Prx II and inhibits the EMT in A549/GR tumors (Fig. 5b, c).
To elucidate the molecular mechanisms by which miR-122 executes its function, we used a Prx II 3′-untranslated region (UTR) luciferase reporter assay. As shown in Fig. 5d, Prx II 3′-UTR luciferase reporter activity was reduced by miR-122, and that reduction was abolished by mutation of the Prx II 3′-TR. Next, we established an A549 pCMV6-Prx II cell line overexpressing Prx II to study the effects of miR-122 on Prx II overexpression in A549 cells. The A549 pCMV6-Prx II cell line was generated as described previously . Then, miR-122 and miR-NC were separately transfected into Prx II-overexpressing cells, and Prx II expression was checked by western blotting. As shown in Fig. 5e, Prx II expression was increased in pCMV6-Prx II cells compared to cells transfected with the empty vector, indicating the successful overexpression of Prx II. However, Prx II expression was downregulated in miR-122-transfected cells compared with miR-NC-transfected cells, indicating that miR-122 inhibited the Prx II expression in A549 cells. An ICC assay further confirmed that miR-122 inhibited Prx II expression (Fig. 5f). These data indicated that miR-122 inhibited tumor growth by directly targeting Prx II in vivo.
MiR-122 targeted HH, Notch, and Wnt/β-Catenin signaling in A549/GR CSCs by inhibiting Prx II
We conducted a series of western blot assays to study the effects of Prx II expression on the HH, Notch, and Wnt/β-Catenin signaling pathways in A549/GR CSCs. As shown in Fig. 6a, the expression levels of CD133, HH signaling-related genes (Shh, Gli-1), Notch signaling-related genes (Notch-1, Hes-1), and β-Catenin were higher in A549/GR cells than in A549/MOCK cells. Those higher expression levels were abolished by Prx II knockdown in A549/GR cells (Fig. 6b). As shown in Fig. 6c, the expression levels of CD133, Shh, Hes-1, and β-Catenin were higher in CD133+ cells than in CD133– cells. However, the expression levels of Gli-1 and Notch 1 did not show significant differences between CD133+ and CD133– cells (Fig. 6c).
Next, we utilized A549/GR CD133+ shPrx II cells (compared to shCON cells) and miR-122-transfected A549/GR CD133+ cells (compared to miR-NC-transfected A549/GR CD133+) cells to study the effects of Prx II on the expression of CD133, HH, and Notch signaling-related genes and β-Catenin. CD133 expression was reduced in shPrx II cells compared with shCON cells and in miR-122-transfected cells compared with miR-NC-transfected cells. The Shh and Gli-1 expression levels were slightly reduced, and Notch 1 and Hes-1 were expressed similarly in shPrx II cells compared with shCON cells. Interestingly, the expression levels of Shh, Gli-1, Notch 1, and Hes-1 decreased significantly in miR-122-transfected A549/GR CD133+ cells compared with miR-NC-transfected cells and A549/GR CD133+ shPrx II cells. β-Catenin expression was downregulated in both shPrx II cells and miR-122-transfected cells, compared with shCON cells and miR-NC-transfected cells (Fig. 6d, e). These data suggested that the inhibition of Prx II expression by miR-122 transfection had more profound inhibitory effects on signaling pathways than did Prx II knockdown in A549/GR CSCs. Finally, we used A549 pCMV6-Prx II cells to study the effects of miR-122 on the aforementioned signaling pathways in A549 cell via Prx II inhibition. Expression of Prx II, CD133, Shh, Gli-1, Notch 1, Hes-1, and β-Catenin decreased in miR-122-transfected A549 pCMV6-Prx II cells (Fig. 6f). Together, these results indicated that miR-122 induced Prx-II-mediated inhibition of the HH, Notch, and Wnt/β-Catenin signaling pathways in A549 cells.
NSCLC is the most common histological form of lung cancer and accounts for 80% of all cases . Previously, we reported the expression levels of Prx isotypes in different NSCLC cell lines resistant to epidermal growth factor receptor-specific tyrosine kinase inhibitors (EGFR-TKIs) . All six Prx isotypes were stably expressed in NSCLC cell lines, except that in A549 cells. Because, Prx II was highly expressed in A549/GR cells, but not in parental A549 cells or other EGFR-TKI-resistant A549 cells due to the methylation of 5′-CCGG-3′ site, the upstream of Prx II gene . Gefitinib interrupts signaling through the EGFR in target cells . Initially, we verified the Prx II-expression levels in three different NSCLC cell lines (A549, H460, and HCC827), along with GR variants of these cell lines. We selected the A549/GR cell line for this study because of the significant difference of Prx II expression, compared with the parental A549 cells. We also showed how Prx II knockdown downregulated the stemness and cell proliferation of NSCLC cells.
As slowly dividing cells with unlimited proliferative potential, CSCs have been found to be responsible for NSCLC formation and a failure to respond to current treatments, including gefitinib [28, 29]. Therefore, we sought to determine whether and how Prx II expression associates with the CSC properties of A549/GR cells. First, we isolated A549/GR stem cells as a subpopulation of cells expressing the CD133 marker (A549/GR CD133+). CD133 is a cell-surface transmembrane glycoprotein that is widely used as a stem cell marker in a variety of normal and tumor tissues [30, 31]. In this study, we found that Prx II expression was higher in CD133+ A549/GR stem cells than in CD133– A549/GR stem cells. Our data clearly showed that the A549/GR CD133+ cell possessed cancer stem-like properties, such as high stemness, cell proliferation, self-renewal ability, and metastasis, indicating that the CSCs were successfully isolated. Therefore, CD133+ cells with high Prx II expression were used for further experiments.
Prx II-knockdown A549/GR CD133+ (A549/GR CD133+ shPrx II) cells were used to ascertain the effect of Prx II knockdown on A549/GR CSCs. A549/GR shCON cells were used as the control after stably transfection with a scrambled shRNA. First, we validated the successful knockdown of Prx II in A549/GR stem cells. Moreover, our data showed that CD133 expression was also downregulated by Prx II knockdown in CSCs. Apoptosis and ROS levels were increased in shPrx II cells. However, the capacities of A549/GR CD133+ cells to proliferate, migrate, invade, and undergo the EMT were inhibited by Prx II knockdown, indicating that Prx II knockdown reduced the metastatic potential. EMT (the loss of the epithelial cell phenotype and the acquisition of the mesenchymal phenotype) is considered a cellular program that modifies tumor cells to facilitate metastasis . Further supporting the role of Prx II in A549/GR stem cells, we demonstrated that Prx II-induced VEGF signaling, as Prx II knockdown inhibited VEGFR2 and STAT3 phosphorylation. In the absence of Prx II, VEGFR2 becomes inactive and no longer responds to VEGF stimulation . Previous reports have shown that the inhibition of STAT3/VEGFR2/VEGF signaling is involved in the anti-angiogenic effects in NSCLC cells . Our previous study also showed that Prx II was positively associated with STAT3/VEGFR2/VEGF signaling and, thus, with angiogenesis in HCC [8, 14]. Thus, our results indicated that Prx II knockdown inhibits angiogenesis in A549/GR CSCs, considering that VEGF and its signaling pathway play a dominant role in angiogenesis . Angiogenesis is one of the most important phenomena involved in sustaining tumor development, proliferation, and metastasis . Prx II was identified as a direct target of miR-122, which induces apoptosis and inhibits the proliferation of HCC cells by inhibiting Prx II . We attempted to determine whether miR-122 associates with high Prx II expression in A549/GR stem cells. We observed a lower baseline level of miR-122 expression in CD133+ cells than in CD133– cells. Therefore, we hypothesized that the lower level of miR-122 expression may be related to higher Prx II expression in A549/GR CSCs. To test this hypothesis, we transfected miR-122 and miR-NC separately into CD133+ cells. Prx II expression was reduced in the miR-122-transfected cells, compared with the miR-NC (control)-transfected cells, demonstrating that miR-122 overexpression inhibited Prx II in A549/GR stem cells. Moreover, our results showed that inhibiting Prx II expression by miR-122 abolished the stem cell properties driven by higher Prx II expression in A549/GR stem cells, including cell proliferation, migration, invasion, EMT, self-renewal ability, and angiogenesis. In support of our hypothesis, our in vivo results showed reduced Prx II expression and tumor growth in miR-122-transfected CD133+ cells. In this study, we found that miR-122 inhibits luciferase activity from the 3′-UTR of Prx II mRNAs. Prx II is not expressed in A549 cells . Thus, to study the effect of miR-122 on Prx II expression in A549 cells, we established a Prx II-overexpressing A549/pCMV6-Prx II cell line. Our results confirmed that miR-122 inhibits Prx II expression in A549 cells. Aberrantly activated HH signaling has been found to drive CSC properties in various types of cancer . However, the role of HH in NSCLC remains controversial, and some studies have reported three subtypes of NSCLCs, depending on the HH activity. A549 cells have high HH activity and are insensitive to existing HH inhibitors due to high Gli-1 expression . Notch signaling promotes proliferation and inhibits apoptosis in NSCLC cells, thereby playing a critical role in tumorigenesis and drug resistance . Upregulation of the Wnt/β-catenin signaling pathway has been reported to activate genes involved in NSCLC cell proliferation, metastasis, and angiogenesis . Furthermore, previous data suggested that Prx II plays a crucial role in activating the HH and Wnt/β-catenin signaling pathways in colorectal cancer cells [11, 12]. Therefore, we studied the association of Prx II with the aforementioned signaling pathways in A549/GR cells and stem cells. Our results clearly showed that miR-122 targeted Prx II mRNA and inhibited the HH, Notch, and Wnt/β-catenin signaling pathways in A549/GR stem cells and A549 cells overexpressing Prx II. Interestingly, these signaling pathways were not significantly inhibited by Prx II knockdown in A549/GR stem cells. Our results indicated that miR-122 has profound inhibitory effects on the HH, Notch, and Wnt/β-catenin signaling pathways and, thus, the stemness characteristics of A549/GR stem cells, compared with Prx II-knockdown A549/GR cells.
In conclusion, we found that Prx II overexpression could be critical for the cancer stem-like properties of A549/GR CSCs. In addition, Prx II-induced stemness characteristics were abolished by miR-122 via Prx II targeting. Therefore, restoring miR-122 expression in A549/GR stem cells may an effective in the therapy against NSCLCs.
Rhee SG, Chae HZ, Kim K. Peroxiredoxins: a historical overview and speculative preview of novel mechanisms and emerging concepts in cell signaling. Free Radic Biol Med. 2005;38:1543–52.
Neumann CA, Cao J, Manevich Y. Peroxiredoxin 1 and its role in cell signaling. Cell Cycle. 2009;8:4072–8.
Jarvela S, Rantala I, Rodriguez A, Kallio H, Parkkila S, Kinnula VL, et al. Specific expression profile and prognostic significance of peroxiredoxins in grade II-IV astrocytic brain tumors. BMC Cancer. 2010;10:104.
Noh DY, Ahn SJ, Lee RA, Kim SW, Park IA, Chae HZ. Overexpression of peroxiredoxin in human breast cancer. Anticancer Res. 2001;21:2085–90.
Kinnula VL, Lehtonen S, Sormunen R, Kaarteenaho-Wiik R, Kang SW, Rhee SG, et al. Overexpression of peroxiredoxins I, II, III, V, and VI in malignant mesothelioma. J Pathol. 2002;196:316–23.
Valdman A, Haggarth L, Cheng L, Lopez-Beltran A, Montironi R, Ekman P, et al. Expression of redox pathway enzymes in human prostatic tissue. Anal Quant Cytol Histol. 2009;31:367–74.
Kwon T, Rho JK, Lee JC, Park YH, Shin HJ, Cho S, et al. An important role for peroxiredoxin II in survival of A549 lung cancer cells resistant to gefitinib. Exp Mol Med. 2015;47:e165.
Chandimali N, Jeong DK, Kwon T. Peroxiredoxin II regulates cancer stem cells and stemness-associated properties of cancers. Cancers. 2018;10:305.
Park YH, Kim SU, Lee BK, Kim HS, Song IS, Shin HJ, et al. Prx I suppresses K-ras-driven lung tumorigenesis by opposing redox-sensitive ERK/cyclin D1 pathway. Antioxid Redox Signal. 2013;19:482–96.
Gao F, Griffin N, Faulkner S, Rowe CW, Williams L, Roselli S, et al. The neurotrophic tyrosine kinase receptor TrkA and its ligand NGF are increased in squamous cell carcinomas of the lung. Sci Rep. 2018;8:8135.
Wang R, Wei J, Zhang S, Wu X, Guo J, Liu M, et al. Peroxiredoxin 2 is essential for maintaining cancer stem cell-like phenotype through activation of Hedgehog signaling pathway in colon cancer. Oncotarget. 2016;7:86816–28.
Lu W, Fu Z, Wang H, Feng J, Wei J, Guo J. Peroxiredoxin 2 knockdown by RNA interference inhibits the growth of colorectal cancer cells by downregulating Wnt/beta-catenin signaling. Cancer Lett. 2014;343:190–9.
Dinesch V, Dinesch M, Buruian M. Drug-eluting stent in-stent restenosis and re-restenosis: A hard time story. J Saudi Heart Assoc 2017; 29:73-74.
Kwon T, Bak Y, Park YH, Jang GB, Nam JS, Yoo JE, et al. Peroxiredoxin II is essential for maintaining stemness by redox regulation in liver cancer cells. Stem Cells. 2016;34:1188–97.
Fang L, Cai J, Chen B, Wu S, Li R, Xu X, et al. Aberrantly expressed miR-582-3p maintains lung cancer stem cell-like traits by activating Wnt/beta-catenin signalling. Nat Commun. 2015;6:8640.
Koh H, Park H, Chandimali N, Huynh DL, Zhang JJ, Ghosh M, et al. MicroRNA-128 suppresses paclitaxel-resistant lung cancer by inhibiting MUC1-C and BMI-1 in cancer stem cells. Oncotarget. 2017;8:110540–51.
Jin D, Lee H. Prioritizing cancer-related microRNAs by integrating microRNA and mRNA datasets. Sci Rep. 2016;6:35350.
Jopling C. Liver-specific microRNA-122: biogenesis and function. RNA Biol. 2012;9:137–42.
Ma L, Liu J, Shen J, Liu L, Wu J, Li W, et al. Expression of miR-122 mediated by adenoviral vector induces apoptosis and cell cycle arrest of cancer cells. Cancer Biol Ther. 2010;9:554–61.
Ma D, Jia H, Qin M, Dai W, Wang T, Liang E, et al. MiR-122 induces radiosensitization in non-small cell lung cancer cell line. Int J Mol Sci. 2015;16:22137–50.
Diao S, Zhang JF, Wang H, He ML, Lin MC, Chen Y, et al. Proteomic identification of microRNA-122a target proteins in hepatocellular carcinoma. Proteomics. 2010;10:3723–31.
Ham SY, Kwon T, Bak Y, Yu JH, Hong J, Lee SK, et al. Mucin 1-mediated chemo-resistance in lung cancer cells. Oncogenesis. 2016;5:e185.
Park EK, Lee JC, Park JW, Bang SY, Yi SA, Kim BK, et al. Transcriptional repression of cancer stem cell marker CD133 by tumor suppressor p53. Cell Death Dis. 2015;6:e1964.
Sreepadmanabh M, Toley BJ. Investigations into the cancer stem cell niche using in-vitro 3-D tumor models and microfluidics. Biotechnol Adv. 2018;36:1094–110.
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74.
Heist RS, Engelman JA. SnapShot: non-small cell lung cancer. Cancer Cell. 2012;21:448–e2.
Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA. 2004;101:13306–11.
Bartucci M, Svensson S, Romania P, Dattilo R, Patrizii M, Signore M, et al. Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapy. Cell Death Differ. 2012;19:768–78.
Kobayashi I, Takahashi F, Nurwidya F, Nara T, Hashimoto M, Murakami A, et al. Oct4 plays a crucial role in the maintenance of gefitinib-resistant lung cancer stem cells. Biochem Biophys Res Commun. 2016;473:125–32.
Wu Y, Wu PY. CD133 as a marker for cancer stem cells: progresses and concerns. Stem Cells Dev. 2009;18:1127–34.
Lundholm L, Haag P, Zong D, Juntti T, Mork B, Lewensohn R, et al. Resistance to DNA-damaging treatment in non-small cell lung cancer tumor-initiating cells involves reduced DNA-PK/ATM activation and diminished cell cycle arrest. Cell Death Dis. 2013;4:e478.
Cai J, Fang L, Huang Y, Li R, Xu X, Hu Z, et al. Publisher Correction: Simultaneous overactivation of Wnt/beta-catenin and TGFbeta signalling by miR-128-3p confers chemoresistance-associated metastasis in NSCLC. Nat Commun. 2018;9:16196.
Kang DH, Lee DJ, Lee KW, Park YS, Lee JY, Lee SH, et al. Peroxiredoxin II is an essential antioxidant enzyme that prevents the oxidative inactivation of VEGF receptor-2 in vascular endothelial cells. Mol Cell. 2011;44:545–58.
Lee H, Lee HJ, Bae IJ, Kim JJ, Kim SH. Inhibition of STAT3/VEGF/CDK2 axis signaling is critically involved in the antiangiogenic and apoptotic effects of arsenic herbal mixture PROS in non-small lung cancer cells. Oncotarget. 2017;8:101771–83.
Maione P, Sgambato A, Casaluce F, Sacco PC, Santabarbara G, Rossi A, et al. The role of the antiangiogenetic ramucirumab in the treatment of advanced non small cell lung cancer. Curr Med Chem. 2017;24:3–13.
Lin EH, Kao YR, Lin CA, Kuo TY, Yang SP, Hsu CF, et al. Hedgehog pathway maintains cell survival under stress conditions, and drives drug resistance in lung adenocarcinoma. Oncotarget. 2016;7:24179–93.
Yuan Z, Goetz JA, Singh S, Ogden SK, Petty WJ, Black CC, et al. Frequent requirement of hedgehog signaling in non-small cell lung carcinoma. Oncogene. 2007;26:1046–55.
Zou B, Zhou XL, Lai SQ, Liu JC. Notch signaling and non-small cell lung cancer. Oncol Lett. 2018;15:3415–21.
Shukla S, Sinha S, Khan S, Kumar S, Singh K, Mitra K, et al. Cucurbitacin B inhibits the stemness and metastatic abilities of NSCLC via downregulation of canonical Wnt/beta-catenin signaling axis. Sci Rep. 2016;6:21860.
This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (2017R1D1A1B03028188).
N.C., D.K.J., and T.K. design performed experiments, analyzed data, and wrote the manuscript. D.L.H. and J.J.Z. analyzed data. J.C.L. and D.Y.Y. providing the NSCLC-TKI cell lines. D.K.J. and T.K. designed experiments and wrote the whole manuscript. All authors read and approved the final manuscript.
Conflict of interest
The authors declare that they have no conflict of interest.
About this article
Cite this article
Chandimali, N., Huynh, D.L., Zhang, J.J. et al. MicroRNA-122 negatively associates with peroxiredoxin-II expression in human gefitinib-resistant lung cancer stem cells. Cancer Gene Ther 26, 292–304 (2019). https://doi.org/10.1038/s41417-018-0050-1
Cancer Gene Therapy (2021)
Signal Transduction and Targeted Therapy (2020)